Guido Leoni
YOU?
Author Swipe
View article: 1336 Final Ph1b/2 results for nous-209 monotherapy in lynch syndrome carriers: annual revaccination boosts T cell immunity informing future cancer interception strategies
1336 Final Ph1b/2 results for nous-209 monotherapy in lynch syndrome carriers: annual revaccination boosts T cell immunity informing future cancer interception strategies Open
View article: Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer
Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer Open
View article: Spatial predictors of response to immunotherapy in microsatellite stable metastatic colorectal cancer
Spatial predictors of response to immunotherapy in microsatellite stable metastatic colorectal cancer Open
Microsatellite stable (MSS) colorectal cancers (CRC) are largely unresponsive to immune checkpoint inhibition (ICI), prompting investigation into strategies to enhance sensitivity. The MAYA trial, which utilized temozolomide (TMZ) in MGMT-…
View article: The RNA binding protein LIN28A mediates chromatin dynamics during neuronal differentiation
The RNA binding protein LIN28A mediates chromatin dynamics during neuronal differentiation Open
The transition of embryonic stem cells (ESCs) from pluripotency to lineage commitment is regulated by multiple mechanisms, including chromatin dynamics and both transcriptional and post-transcriptional processes. Recent advances have highl…
View article: 638 Nous-209 vaccine induces shared neoantigen immunogenicity for cancer interception in healthy lynch syndrome carriers: results from phase Ib/II trial
638 Nous-209 vaccine induces shared neoantigen immunogenicity for cancer interception in healthy lynch syndrome carriers: results from phase Ib/II trial Open
View article: Characterization of shared neoantigens in Endometrial Cancer with Microsatellite Instability
Characterization of shared neoantigens in Endometrial Cancer with Microsatellite Instability Open
Endometrial cancer (EC) with microsatellite instability (MSI) are characterized by the accumulation of insertions/deletions at microsatellite sites, mainly mononucleotide repeats (MNRs). These MSI-related mutations lead to the synthesis of…
View article: Data from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
Data from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses Open
Purpose:Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is a vector-based personalized vaccine, expressing…
View article: Supplementary Table 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
Supplementary Table 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses Open
Supplementary Table 1. Representativeness of study participants
View article: Data from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
Data from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses Open
Purpose:Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is a vector-based personalized vaccine, expressing…
View article: Supplementary Figure 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
Supplementary Figure 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses Open
Supplementary Figure 1. IFN-γ ELISpot response post-IVS
View article: Supplementary Figure 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
Supplementary Figure 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses Open
Supplementary Figure 1. IFN-γ ELISpot response post-IVS
View article: Supplementary Table 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
Supplementary Table 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses Open
Supplementary Table 1. Representativeness of study participants
View article: Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Mutation loss in developed CT26 tumors after GAd CD8#5 and CD8#23 vaccine. A) Mice were immunized with mono-epitope GAd CD8#5 or B) CD8#23 vaccines and 14 days later, mice were inoculated s.c. with 2x10^5 CT26 cells. Mutation relative to n…
View article: Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to unravel the features of nAg…
View article: Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Generation of CT26 #5KO and CT26 #23KO cells using CRISPR-Cas9 technology. A) CRISPR/Cas9 strategy used for the generation of CT26 cells lacking of nAg #5. Red arrows represent forward and reverse primers used for PCR. Blue lines 1 and 2 i…
View article: Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Primary tumor challenge with NeoAg #5 knocked out CT26 tumor cells. Mice were immunized with CD8#5 mono-epitope vaccine and after 14 days, mice were s.c. inoculated with CT26 cells or CT26 #5KO cells, resulting in 50% and 0% of tumor free …
View article: Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Primary tumor challenge with NeoAg #5 knocked out CT26 tumor cells. Mice were immunized with CD8#5 mono-epitope vaccine and after 14 days, mice were s.c. inoculated with CT26 cells or CT26 #5KO cells, resulting in 50% and 0% of tumor free …
View article: Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Phenotype characterization of total CD8+ and nAg #23+ CD8+T cells in presence and absence of the “Help”. A) Schematic representation of the experimental set up. B) Representative FACS gating strategy for intratumoral CD8+ T cells. C-D) Phe…
View article: Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Mutation loss in developed CT26 tumors after GAd CD8#5 and CD8#23 vaccine. A) Mice were immunized with mono-epitope GAd CD8#5 or B) CD8#23 vaccines and 14 days later, mice were inoculated s.c. with 2x10^5 CT26 cells. Mutation relative to n…
View article: Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Characterization of neoAg#23 specific T cell subsets in the presence/ absence of T cell “Help”. A) Schematic representation of the experiment. Mice were s.c. injected with CT26 cells and 5 days later, immunized with GAd vaccines CD4+CD8#23…
View article: Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Generation of CT26 #5KO and CT26 #23KO cells using CRISPR-Cas9 technology. A) CRISPR/Cas9 strategy used for the generation of CT26 cells lacking of nAg #5. Red arrows represent forward and reverse primers used for PCR. Blue lines 1 and 2 i…
View article: Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
List of the GAd encoded CT26 neoantigens selected according to: binding predictions for MHC-I (IC50 ≤ 500nM) and MHC-II (binding score ≤ 1); tumor allele frequency (MAF≥ 25%) and RNA expression (mutated RNA reads ≥ 1). The mutated amino ac…
View article: Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
List of the GAd encoded CT26 neoantigens selected according to: binding predictions for MHC-I (IC50 ≤ 500nM) and MHC-II (binding score ≤ 1); tumor allele frequency (MAF≥ 25%) and RNA expression (mutated RNA reads ≥ 1). The mutated amino ac…
View article: Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Phenotype characterization of total CD8+ and nAg #23+ CD8+T cells in presence and absence of the “Help”. A) Schematic representation of the experimental set up. B) Representative FACS gating strategy for intratumoral CD8+ T cells. C-D) Phe…
View article: Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to unravel the features of nAg…
View article: Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Representative numbers of total and #23+ CD8+ T cells in tumor and spleen of Help versus non Help vaccine. A) Experimental scheme, FACS gating strategy with representative FACS plots of intratumoral #23+ CD8+ T cells in Help group and untr…
View article: Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Representative numbers of total and #23+ CD8+ T cells in tumor and spleen of Help versus non Help vaccine. A) Experimental scheme, FACS gating strategy with representative FACS plots of intratumoral #23+ CD8+ T cells in Help group and untr…
View article: Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine Open
Characterization of neoAg#23 specific T cell subsets in the presence/ absence of T cell “Help”. A) Schematic representation of the experiment. Mice were s.c. injected with CT26 cells and 5 days later, immunized with GAd vaccines CD4+CD8#23…
View article: Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses Open
Purpose: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is a vector-based personalized vaccine, expressin…
View article: Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine Open
Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous pri…